** Tango Therapeutics' TNGX.O shares down 3.2% to $29.95 post-market as it looks to raise equity

** TNGX kicks off $500 mln stock offering

** JP Morgan, Leerink, Cantor Fitzgerald and Stifel joint bookrunners

** TNGX stock soared 53% to close at record high $30.93 on Mon after co's experimental pancreatic cancer drug vopimetostat, in combination with Revolution Medicines' RVMD.O daraxonrasib, showed strong early results in a small study

** TNGX intends to use net offering proceeds for general purposes, including R&D, expenses for pivotal trial and preparation for potential commercialization of one or more of its product candidates, among other purposes, per the prospectus

** Boston, Massachusetts-based TNGX has ~144.6 mln shares outstanding for about $4.5 bln current market cap

** At close, stock up 249% YTD

** 10 of 12 analysts rate the stock "strong buy" or "buy", 2 "hold"; median PT $35, according to LSEG data